Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
about
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular diseaseUric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitusFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewDetermination of cortisol production rates with contemporary liquid chromatography-mass spectrometry to measure cortisol-d(3) dilution after infusion of deuterated tracer.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemiaRare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.In vitro antimalarial activity and drug interactions of fenofibric acidAbsolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.Treatment of dyslipidaemia in HIV-infected persons.Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibratePPAR-α as a key nutritional and environmental sensor for metabolic adaptation.Has nanotechnology led to improved therapeutic outcomes?Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.Rhabdomyolysis: a case study exploring the possible side effect of lipid lowering medication by a HIV positive patient taking a protease inhibitor.In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.Normalization of metabolic syndrome using fenofibrate, metformin or their combination.The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies.Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
P2860
Q21342788-8F57F8DB-F797-49C5-B6BF-1F43F749BFB1Q24678615-682D919D-40D8-424E-8B88-63E83CDF291AQ24804541-43A42C2A-196A-4F00-BAC3-56C2560A5714Q24815913-2C3BFC76-11AE-4DB6-8CFE-6FF0179A5AA1Q28219328-C16FA8B6-24AE-48BA-B98F-DA5F93693B56Q28220294-E2A487FB-9FD0-4A8F-BCE0-34CDB6FA401AQ33449027-56690284-7343-4905-8719-830EAB3A80A9Q33776187-EEBC5BC1-B468-43F0-96B1-CD4F8D631751Q34153553-A246C988-0278-4D83-A9D0-389E9FDB7FCBQ34628781-F717768B-52D9-4691-A2B1-6A01A0514F96Q35332645-E69EAE6D-93E2-46A9-B890-5477BD4D08D9Q35886146-EEBBB709-3063-4A2C-ABC5-31C420BCBBA0Q36018677-5A833130-859C-477E-AD05-3F0BEF4053DFQ36122865-65F0A7B2-058A-4B6D-82F8-4EAE091E03F7Q36137264-40CBDA40-8495-4968-931D-57E4B096D816Q36222023-09C58F69-9352-4647-9049-F563EDCDF2CDQ36349758-B903CE29-4290-42ED-A73E-61C9B52DFFAAQ36608415-5D940871-C06C-4BE9-9EF5-1F8DFBE280F8Q36805049-A6B3F477-64AC-4B3B-BDAD-1BA4FEB6D002Q36847314-5936C86E-EAD5-43A1-B22D-61E725E64921Q36897732-5615460F-BAB2-4183-9F61-9D1F777844ABQ37019924-0155BA6D-7EBE-4074-A721-D03153D01C65Q37140555-98EB6C0B-3882-4E61-A6F4-F3167601B0BAQ37616202-A67B3045-3854-4E7E-B304-04435B6513CBQ37970730-2EA94E0A-C523-43E8-A7C6-02417B232FDEQ38856838-0263A5C0-B706-45C2-BD9E-B3D829F630BAQ39335668-EAE3D871-DF8B-440A-91A4-5C53E00452E3Q40274682-0ECCB3BC-91B8-4A23-B8AD-39E0A5479821Q41113376-40062E94-EB95-4B9A-828C-BBD39206123EQ43171597-3ACB15C0-261E-44A9-B148-8CC1E0654B4FQ44652488-0E79A994-C3C0-4331-A5E1-26FA4B627DC7Q46607014-72ED8303-3968-4A03-A297-7C784AAEBF3BQ46959415-DC663E05-3A28-4CA4-8A84-3DF9D1B627E2Q46962775-CD367630-04FA-4917-90F6-7E6772D536E2Q49853377-51518377-5D92-439A-A248-2DCF6F045CF7Q51492959-CAC0AFB0-269F-40AD-A122-B37E0D0F95E2
P2860
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@ast
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@en
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@nl
type
label
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@ast
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@en
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@nl
prefLabel
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@ast
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@en
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@nl
P2860
P1433
P1476
Micronised fenofibrate: an upd ...... e management of dyslipidaemia.
@en
P2093
Douglas Ormrod
P2860
P304
P356
10.2165/00003495-200262130-00013
P577
2002-01-01T00:00:00Z
P6179
1015455302